Curebase, AppliedVR Announce Agreement for Multiple VR Therapy Clinical Trials | News

SAN FRANCISCO i LOS ANGELES, August 26, 2021 / PRNewswire / – Curebase, a company committed to democratizing access to clinical trials, and AppliedVR, a pioneer in advancing the next generation of digital medicine, today announced a one-year partnership where AppliedVR will deploy the Curebase platform to conduct five clinical trials evaluating the effectiveness of virtual reality (VR) therapy to treat chronic pain.

AppliedVR is the most evidence-based therapeutic RV platform for the treatment of pain and has been used by more than 30,000 patients in more than 240 of the best health systems worldwide. Clinical trials with Curebase will focus on the study of a self-administered VR VR therapy program at home, with Curebase software managing online patient recruitment, consent, participant participation, and the collection of results from the patient. The Curebase platform will also support clinical workflows, including the randomization scheme, research coordinator communication, IP monitoring and coordination of VR headsets, and trial kit distribution.

“The Curebase approach allows AppliedVR to deliver a high-end patient experience for participants from anywhere in the country,” he said. Tom Lemberg, CEO and founder of Curebase. “AppliedVR’s commitment to five studies over a one-year period, through the Curebase decentralized clinical trial platform, demonstrates how our technology and infrastructure provide the best virtual research solution in the industry. This demonstrates more how Curebase has uniquely met the needs of the growing digital therapeutic market that matches innovation in digital medicines with equally innovative research solutions.Thanks to our unique and established approach, Applied VR will have the power to hire faster, experience better rates test compliance and a faster search history “.

AppliedVR offers virtual reality-based treatments that address the complexity of chronic pain. Rooted in behavioral cognitive therapy and mindfulness, AppiedVR’s EaseVRx includes a comprehensive approach that encompasses the biological, psychological, and social factors that influence how people experience chronic pain. After extensive testing, EaseVRx recently became one of the first therapeutic products based on virtual reality. receive “Advanced Device Designation” of the U.S. Food and Drug Administration (FDA) to treat treatment-resistant fibromyalgia and chronic intractable back pain. In February, the company announced results of his fundamental essay, which were published in Journal of Medical Internet Research (JMIR), finding that RV can be a holistic treatment for chronic pain. Moving forward, the Curebase platform will help participants in the AppliedVR study each day to comply with research protocols and report basic data on results.

“Virtual reality has enormous potential to improve and reduce the cost of how we treat chronic pain, while reducing US dependence on pharmacological interventions. Demonstrating that it requires effective clinical trials and Curebase technology gives us an extreme extremely easy to use. A highly workflow-oriented solution specializing in digital therapeutic study designs, ”he said. Josh Sackman, president and co-founder of AppliedVR. “This gives us confidence that our research participants will have extensive experience in being enrolled in our study and reduces the burden for our research staff performing complex decentralized trials.”

About Curebase

At Curebase, our mission is to bring quality medical innovations to patients faster and improve human well-being through more efficient clinical studies. We are demonstrating that clinical research can be radically accelerated if we empower doctors everywhere to enroll patients in the communities where they live. By applying cutting-edge clinical programs and remote study management techniques to the problem, we reinvent clinical trials and research from the ground up. For more information, visit www.curebase.com.

About AppliedVR

AppliedVR is a pioneer in the next generation of digital medicines to provide safe and effective virtual reality (VRx) therapies that address unmet needs and improve clinical outcomes for patients with serious health conditions. Its evidence-based noninvasive treatments submerge and involve patients to help achieve measurable clinical outcomes. As the most widely used and deeply researched therapeutic VR platform, AppliedVR is the first company to offer VR therapy to wide availability in clinical care, as it has immersed more than 60,000 patients in more than 200 hospitals. AppliedVR has established world-class trade and research partnerships and continues to build the infrastructure to accelerate the massive adoption of VRx. For more information about AppliedVR, Inc., visit https://appliedvr.io/.

Contact with the media: Grace Vinton, Account Manager, [email protected]

See original content to download multimedia content: https://www.prnewswire.com/news-releases/curebase-appliedvr-announce-agreement-to-run-multiple-vr-therapy-clinical-trials-301363115.html

SOURCE Curebase



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *